Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients
A Multi-Center, Open Label Study To Evaluate Long Term Safety Of Caduet In Patient With Both Of Hypertension And Hypercholesterolemia, Or With Both Of Angina Pectoris And Hypercholesterolemia
Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
This PHASE4 trial investigates Angina Pectoris and Hypercholesterolemia and is currently completed. Pfizer's Upjohn has merged with Mylan to form Viatris Inc. leads this study, which shows 8 recorded versions since 2010 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Feb 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Feb 2021 [monthly]
Completed PHASE4
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
Aug 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Adachi-ku, Japan , Amagasaki, Japan , Arakawa-ku, Japan , Dazaifu, Japan , Fujimi, Japan , Fukuoka, Japan , Kawaguchi, Japan , Kawasaki, Japan , Kitakyushu, Japan , Kobe, Japan and 8 more locations